Update on the genus Trichosporon

被引:127
作者
Chagas-Neto, Thomas C. [1 ]
Chaves, Guilherme M. [1 ]
Colombo, Arnaldo L. [1 ]
机构
[1] Univ Fed Sao Paulo, Div Infect Dis, BR-04037002 Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
emergent pathogen; yeast identification; epidemiology; Trichosporon; antifungal drugs;
D O I
10.1007/s11046-008-9136-x
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Trichosporon spp. are widely distributed in nature and can occasionally belong to the human microbiota. For many years, the unique species of the genus, Trichosporon beigelli, was only known as an environmental and saprophytic fungus occasionally found as the etiological agent of white piedra. However, case reports of invasive trichosporonosis have been frequently published and the genus is currently considered the second most common agent of yeasts disseminated infections. Based on molecular analysis, the taxon T. beigelli was replaced by several species and the taxonomy of the genus was progressively modified. Despite the reported increase of Trichosporon infections refractory to conventional antifungal drugs, there are only a few studies investigating in vitro susceptibility of Trichosporon spp. to new compounds. Difficulties on different species identification as well as the lack of standardized sensitivity tests in vitro, contribute to the limited information available on epidemiology, diagnosis and therapeutics of trichosporonosis.
引用
收藏
页码:121 / 132
页数:12
相关论文
共 87 条
  • [1] Trichosporon asahii fatal infection in a non-neutropenic patient after orthotopic liver transplantation
    Abdala, E
    Lopes, RI
    Chaves, CN
    Heins-Vaccari, EM
    Shikanai-Yasuda, MA
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2005, 7 (3-4) : 162 - 165
  • [2] AZOLE THERAPY FOR TRICHOSPORONOSIS - CLINICAL-EVALUATION OF 8 PATIENTS, EXPERIMENTAL-THERAPY FOR MURINE INFECTION, AND REVIEW
    ANAISSIE, E
    GOKASLAN, A
    HACHEM, R
    RUBIN, R
    GRIFFIN, G
    ROBINSON, R
    SOBEL, J
    BODEY, G
    [J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) : 781 - 787
  • [3] COMPARATIVE EFFICACIES OF AMPHOTERICIN-B, TRIAZOLES, AND COMBINATION OF BOTH AS EXPERIMENTAL-THERAPY FOR MURINE TRICHOSPORONOSIS
    ANAISSIE, EJ
    HACHEM, R
    KARYOTAKIS, NC
    GOKASLAN, A
    DIGNANI, MC
    STEPHENS, LC
    TINU, CK
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (11) : 2541 - 2544
  • [4] EMERGING FUNGAL PATHOGENS
    ANAISSIE, EJ
    BODEY, GP
    RINALDI, MG
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (04) : 323 - 330
  • [5] Arce M., 1998, Anais Brasileiros de Dermatologia, V73, P13
  • [6] Superficial mycotic infections of the foot in a native pediatric population:: A pathogenic role for Trichosporon cutaneum?
    Archer-Dubon, C
    Orozco-Topete, R
    Leyva-Santiago, J
    Arenas, R
    Carbajosa, J
    Ysunza, A
    [J]. PEDIATRIC DERMATOLOGY, 2003, 20 (04) : 299 - 302
  • [7] Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates
    Arikan, S
    Hasçelik, G
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 43 (02) : 107 - 111
  • [8] Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia
    Asada, Noboru
    Uryu, Hidetaka
    Koseki, Mihoko
    Takeuchi, Masami
    Komatsu, Masaru
    Matsue, Kosei
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 43 (04) : E39 - E41
  • [9] Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B
    Bassetti, M
    Bisio, F
    Di Biagio, A
    Pierri, I
    Balocco, M
    Soro, O
    Cruciani, M
    Bassetti, D
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) : 575 - 577
  • [10] Behrend G, 1890, BERLIN KLIN WSCHR, V27, P464